| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b data readout example | VTX3232 Early Parkinson’s disease | Phase 2b | — | Small Molecules | - | ||
Phase 2b data readout example | VTX3232 Early Parkinson’s disease | Phase 2b | — | Small Molecules | - | ||
Phase 2b data readout example | VTX3232 Early Parkinson’s disease | Phase 2b | — | Small Molecules | - |
Recent Updates
Recently added Catalysts
Ventyx Biosciences, Inc.$14
+0.01 (+0.07%)
Market Cap
1.00 B
EPS
-1.50
P/E Ratio
-
Value Trade
76.26 M
SEC Financials
Q3 2025Dilution Risk
R&D Expenses
17.71 M
Total Assets
211.47 M
Total Liabilities
20.10 M
Equity
191.36 M
D/E Ratio
12,345
0.36 %
Week
0.29 %
1 Month
77.55 %
3 Month
444.75 %
6 Month
-24.93 %
5 Year
-24.93 %
All Time
Cash Data
Cash Position
192.64 M
Monthly Burn
8.29 M
Runway
18.9 mo
Burn Trend
SEC Filing
Nov 6, 2025
Overview
Volume
5.45 M
52 Week Range
0.78 - 25
% held by Insiders
12.9 %
% held by Institutions
75.92 %
Enterprise Value
822.04 M
Total Shares
71.71 M
Short %
9.48 %
Float Shares
51.27 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VTX3232 | Parkinson's disease | Phase 2a | 2025-08-08 | |||
VTX3232 | Parkinson's disease | Phase 2a | 2025-08-08 | |||
VTX3232 | Parkinson's disease | Phase 2a | 2025-08-08 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VTYX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Ventyx Biosciences, Inc. (VTYX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
VTYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VTYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VTYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VTYX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
VTYX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VTYX ranks across every disease it competes inCompetitive Position is a premium feature
See how VTYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial